Alkermes plc

ALKS ·Healthcare, Drug Manufacturers - General, Ireland
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $241.7M $367.1M $355.8M $-158.3M $-48.2M $-110.9M $-196.6M $-139.3M
Depreciation & Amortization $27.2M $28.5M $74.9M $77.9M $78.7M $81.9M $80.4M $103.7M
Depreciation $31.1M $27.4M $25.7M $26.3M $23.3M $42.4M $40.1M $38.5M
Amortization — $1.1M $35.7M $36.4M $38.1M $39.5M $40.4M $65.2M
Stock-Based Compensation $98.7M $96.6M $100.9M $94.3M $87.6M $90.2M $101.0M $105.4M
Net Cash from Operating Activities $520.8M $439.1M $401.4M $21.0M $101.7M $82.8M $72.1M $99.3M
Investing Activities
Capital Expenditures $40.4M $33.5M $48.0M $38.3M $28.0M $42.2M $90.9M $69.4M
Business Acquisitions — — — — — — $8.9M —
Net Cash from Investing Activities $295.5M $-111.3M $53.4M $-64.5M $-66.2M $-11.5M $-141.8M $-22.2M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — $200.3M — — — — — —
Net Cash from Financing Activities $12.4M $-494.1M $-289.7M $-1.6M $29.1M $-2.2M $6.8M $-1.6M
Net Change in Cash $828.6M $-166.3M $165.0M $-45.1M $64.6M $69.2M $-63.0M $75.5M
Free Cash Flow $480.3M $405.6M $353.3M $-17.2M $73.7M $40.6M $-18.9M $29.9M
← Newer Page 1 of 2 Older →